Impact of the J Project on progress of primary immunodeficiency care in Ukraine

ALLA VOLOKHA1, ANASTASIA BONDARENKO1, LIUDMYLA CHERNYSHOVA1, ANNA HILFANOVA1, YURIY STEPANOVSKY1, OKSANA BOYARCHUK2, LARYSA KOSTYUCHENKO1

1Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
2Horbachevsky Ternopil State Medical University, Ukraine

Abstract
The J Project is a Central-Eastern European collaborative program in the field of physician education and clinical research aimed at improving the clinical care and diagnosis of primary immunodeficiency disorders (PIDs). Ukraine was one of the first to participate in the project, which allowed us to join the whole European PID community. Since 2004, the country has been holding annual J Project meetings with the involvement of new regions. The spread of the J Project impact has contributed to significantly improved early PID diagnosis in Ukraine. Progress has been made not only in identifying patients but also in arranging the treatment. The assistance in genetic diagnosis made it possible to detect PIDs, study their features, and improve approaches to the management. This also gave an impetus to the development of regional PID centers and participation in scientific research. Of utmost importance is the cooperation with colleagues from Poland, Hungary, and Belarus, who are active members of the J Project.

Key words: children, primary immunodeficiency, registry, network, Ukraine.

Introduction
In 1996, for the first time in Ukraine, an educational program in pediatric immunology started at the Department of Pediatric Infectious Diseases and Pediatric Immunology, Shupyk NMAPE (Kyiv, Ukraine). The immunologists of the department focused their efforts on the detection of children with primary immunodeficiency diseases (PIDs). Back then, there was a lack of data on the presence and number of PIDs in Ukraine. In order to improve the quality of health care for children with congenital immune pathologies, the Kyiv Children’s Immunological Centre was established in 1999 at the initiative of Professor L. Chernyshova. Owing to this step, pediatric PID patients got access to the appropriate health care. Since its creation, the Kyiv Children’s Immunological Centre has been working as a national reference center providing assistance in the diagnosis and treatment of PID patients from all regions of Ukraine. The department employees have been advising children from Kyiv and other cities and regions of Ukraine.

To overcome the major problem related to the low awareness and alertness of primary care physicians in managing children with PID, within the J Project, an educational campaign was launched for physicians under the guidance of Professor Laszlo Marodi in March 2004 [1]. The first Ukrainian J Project meeting was held in Kyiv. Pediatric immunologists from various countries – participants of the J Project – attended the event.

At that time, there were already pediatricians who specialized in pediatric immunology at the Department of Pediatric Infectious Diseases and Immunology, Shupyk NMAPE. Pediatric immunologists worked in all central cities of Ukrainian regions. Furthermore, other reference centers (Lviv, Kharkiv) and regional centers were established.

Annually, the J Project covered a new region in Ukraine, engaging hundreds of clinicians. Meetings were held in various regions of the country. Since 2004, 16 J Project Ukraine meetings have been held, covering more than half of the country’s regions (Fig. 1). Educational meetings have been conducted mainly in regions with a lower number of PID patients. They have involved lectures, workshops and case presentations for primary care physicians on early PID detection. Overall, several hundred physicians attended each J Project meeting, including pediatricians, general practitioners, and other health professionals. Educational materials on warning signs and
early PID diagnosis have been distributed among physicians. Within the programs of all those meetings, there have been set up advanced educational sessions for pediatric immunologists.

Representatives from different countries, including Hungary, Poland, Macedonia, Italy, Czech Republic, Turkey, Belarus, Russia, Latvia, Moldova and Greece, have taken part in the Ukrainian J Project meetings.

Due to the spread of the J Project activity in many regions of the country, the diagnosis of PIDs has been improved significantly. In contrast to 1997, when the first two patients were found to have Bruton’s disease, more than 1,000 patients were diagnosed with PID in 2020 (Fig. 2). In 2003, the National Registry for Primary Immunodeficiencies was implemented in Ukraine.

The J Project promoted the creation of a network of doctors, biologists and scientists in Eastern and Central Europe for better cooperation in health care and research into PID. Such fruitful cooperation of pediatric immunologists from various countries within J Project enabled us to diagnose rare PIDs and confirm them with genetic diagnosis.

Most J Project countries, including Ukraine, do not yet have their own genetic diagnosis and still require support from Western Europe and USA centers. One of the goals of the J Project, which is defined by the Antalya Declaration (http://www.jprojectnetwork.com/Page/AboutJProject/Antalyadeclaration), is free access to genetic testing for all patients. Debrecen PID Center led by Professor Laszlo Marodi had never abandoned any specimen sent for genetic diagnosis until 2015, when the laboratory was unreasonably closed.

Prevalence and incidence of primary immunodeficiency disease

The prevalence of PID in Ukraine was estimated by calculation of the number of living PID patients per 100,000 inhabitants. We used the data collected for the PID registry. Prevalence calculations were based on Ukrainian population data sourced from the National Statistics Committee of Ukraine. The incidence of PID was calculated using data on the year of birth of patients and the number of live births in the respective year.

To date, the overall prevalence of PID in Ukraine is 1.78 cases/100,000 inhabitants (in 2014, the prevalence was 1.22/100,000, in 2017 it was 1.46/100,000). Estimates of PID prevalence do not include the patients with transient hypogammaglobulinemia of infancy and benign childhood neutropenia (Fig. 3).
The incidence of PIDs cases calculated over an 18-year period (2001-2019), is 10.0 per 100,000 live births. When comparing the data before and after initiating the J Project in Ukraine, we found striking differences in values with the incidence of PID being 5.0/100,000 children born alive by 2004, and 9.9/100,000 children born alive between 2004 and 2019.

National primary immunodeficiency disease registry

The National Registry for Primary Immunodeficiencies was established in 2015 and the data on all patients with PID diagnosed in 27 regions of Ukraine between 1996 and 2014 were incorporated. The information on patients from Crimea and Sevastopol collected until 2013 was also included. All pediatric immunologists experienced in the care of PID patients were invited to collaborate with the Kyiv Children’s Immunological Centre. The registry is regularly updated. Most PID patients are monitored at the Department of Pediatric Infectious Diseases and Immunology. The registry also includes the information on PID patients registered at other immunological centers of Ukraine (Lviv, Kharkiv) [2].

We collected the data in paper format, including demographics and key medical data (date of PID diagnosis, date of symptom onset, main clinical features, laboratory tests) and created the database. PIDs were classified according to the International Union of Immunological Societies’ (IUIS) criteria [3]. The patients were diagnosed with PID pursuant to the guidelines of the European Society for Immunodeficiencies (ESID) [4].

The registry database was established and hosted by the Kyiv Children’s Immunological Centre, which functions as a reference center. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Ethics Committee of Shupyk NMAPE and local ethics committees of participating centers. Informed consent was obtained from patients or parents prior to inclusion in the registry.

At the beginning of 2020, the total number of patients who were entered into the Ukrainian PID Registry was 1,123 [684 (60.9%) males, 439 (39.1%) females]. Of these, there were 953 live patients in the registry, 136 (12.1%) patients died and 34 patients were lost to follow-up. Of the living patients, children (n = 680 of 953) outnumbered adults, 273 adult patients were aged > 18 years. Among the deceased patients, 125 died in childhood, 11 patients died aged > 18 years.

The PID Registry included 187 children with transient hypogammaglobulinemia of infancy and benign childhood neutropenia, whose manifestations disappeared with age. Excluding the patients with the above transient conditions, 766 living PID patients are being followed up; among them 257 patients are aged > 18 years.

In general, the distribution of the main PIDs in Ukraine is similar to the structure in European countries (Fig. 4). Compared to the European registry, there is the same pattern with regard to the proportion of antibody deficiencies (54% ESID data), combined immunodeficiencies with syndromic features (18%) and combined immunodeficiencies (7%) [5, 6]. The Ukrainian registry presents 64 specified nosological PID entities. Antibody deficiencies are the most common subcategory of PID [590/1,123 (52.54%)], followed by combined immunodeficiencies (CID) with associated or syndromic features [244/1,123 (21.73%), CID [82/1,123 (7.3%)], congenital defects of phagocyte number and function [86/1,123 (7.66%)], diseases of immune dysregulation [29/1,123 (2.54%)], complement deficiencies [20/1,123 (1.78%)] and autoinflammatory disorders [20/1,123 (1.34%)].

The most common nosological entities are minor antibody deficiencies: selective IgA deficiency – 206 (18.3%) and transient hypogammaglobulinemia of infancy – 220 (19.5%). Among the severe immunodeficiencies,
the most represented are X-linked agammaglobulinemia – 66 (5.8%), chronic granulomatous disease (CGD) – 28 (2.5%) and CID with syndromic features, including syndrome DiGeorge – 71 (6.3%), Nijmegen syndrome – 53 (4.7%), ataxia-telangiectasia – 51 (4.5%), and Wiskott-Aldrich syndrome (WAS) – 29 (2.6%). Severe combined immunodeficiencies (SCID) account for 63 cases (5.6%).

To date, PID has been genetically confirmed in 300 patients in Ukraine, who constitute 26.7% of all patients in the PID registry (Table 1).

**Education campaign**

Despite the progress in PID diagnosis in Ukraine over the last 15 years, we have encountered the challenges related to the recognition of PIDs, especially some novel immunodeficiency groups (defects of immune dysregulation, autoinflammatory disorders, defects of innate and intrinsic immunity).

In 2017, the Ukrainian Association of Pediatric Immunology initiated the series of clinical conferences named RAPID (Rapid Diagnostics of PID) with the main aim of improving diagnosis in regions through on-site patient counseling.

In 2018, the J Project meetings in Ukraine changed the format from focusing only on primary care physicians to the involvement of health professionals of other subspecialties. A meeting with hematologists was held in 2018 to increase the number of identified patients with immune defects and cytopenias that had been virtually undiagnosed before. This was also facilitated by the expansion of genetic diagnosis through commercially available panel sequencing (Invitae Laboratory, USA). Collaboration with hematologists has also triggered the development of bone marrow transplantation in Ukraine. As of today, a registry of bone marrow donors in Ukraine has been established and it is constantly being updated (https://ubmdr.org).

Improved PID diagnosis and treatment in Ukraine contributed to the increased number of patients surviving to adulthood. This posed new challenges to the immunological community concerning the continuity in the management of patients between pediatric and adult specialists involved in PID management. For the first time, the J Project Meeting in Ternopil (2019) brought together our country’s pediatric and adult immunologists. A consensus was reached regarding the joint actions to be taken and implementation of the joint patient registry. For the first time, an adult patient with autoinflammatory disorder (ADA2 deficiency) was referred for transplantation.

We believe that focusing on the interdisciplinary collaboration is a promising direction for the further development of the J Project in Ukraine. Obviously, severe cases are most concentrated among doctors of different specialties (pulmonologists, rheumatologists, hematologists, etc.). Therefore, it is important to increase the alertness among primary care physicians, but also among doctors of other specialties who are not sufficiently aware of PID issues today. In the future, J Project meetings together with pulmonologists, rheumatologists, cardiologists, and allergists are planned.

**Collaboration in scientific research**

The J Project has a close professional partnership with the ESID. Thanks to the J Project, pediatric immunologists from Ukraine have entered the European medical space [7, 8].

![Fig. 4. Distribution of primary immunodeficiency disorder (PID) groups in primary immunodeficiency registry in Ukraine](image-url)
Cooperation in the field of PID was established with colleagues from Poland, Hungary, Belarus, and Iran [9, 10].

The J Project has also gradually transformed from an educational campaign for physicians to a collaborative research program aimed at identifying the mutational spectrum of genes associated with PID and analyzing unique genotype-phenotypic relationships in Eastern and Central Europe. Thus, in 2011, two groups of researchers from different countries (one group included L. Chernyshova, A. Bondarenko, and V. Chernyshov from Ukraine) described a new variant of chronic mucocutaneous candidiasis (CMCC) caused by gain-of-function mutations in the NLRP12 gene [11-14].

As of today, within the framework of the Cooperation Agreement, a scientific project is jointly being implemented with the Republican Centre of Pediatric Oncology, Hematology and Immunology of Belarus – “The genetic landscape of SCID in Eastern Europe” – according to the grant of the scientific program CHILDREN (Jeffrey Modell Foundation, JMF) [15, 16].

The support in genetic diagnosis enabled us to diagnose several PIDs and study the clinical features and prevalence of immunodeficiencies in the Ukraine. The results of these scientific studies were summarized in research theses and articles, presented at conferences [17-21]. Given that PIDs are rare diseases, we can make reasonable conclusions only based on collecting, summarizing and analyzing data from different countries. The results of multicenter studies of patients with various PIDs are important for the development of novel methods of treatment. Such results are presented in publications of scientific teams combining efforts of scientists from different countries [22-26].

### Table 1. Genetic defects of 300 primary immunodeficiency disorder (PID) patients in Ukraine

| Group of PIDs | Affected genes (n; %) |
|---------------|-----------------------|
| Immunodeficiencies affecting cellular and humoral immunity | CD40LG (5; 1.66%), MALT1 (1; 0.33%), RAG1 (5; 1.66%), DOCK8 (3; 1.0%), IL7R (1; 0.33%), ADA (3; 1.0%), IL-2RG (4; 1.33%), IL-2Rα (1; 0.33%), IL10R (1; 0.33%), DCLRE1C (3; 1.0%) |
| Combined immunodeficiencies with associated or syndromic features | WAS (21; 7.0%), ATM (11; 3.0%), NBS1 (52; 17.3%), STAT3 (6; 2.0%), Del 22q11.2 (32; 10.66%), SPINK5 (4; 1.33%), PMP2 (2; 0.66%), KMT2D (1; 0.33%) |
| Predominantly antibody deficiencies | BTK (34; 11.3%), PIK3CD (2; 0.66%), PIK3R1 (2; 0.66%), TNFRSF13B (11; 3.66%), IGLL1 (1; 0.33%), NFKB2 (2; 0.66%), AICDA (2; 0.66%) |
| Diseases of immune regulation | SH2D1A (2; 0.66%), TNFRSF6 (5; 1.66%), CXCR4 (3; 1.0%), CTLA4 (4; 1.33%), AIRE (5; 1.66%), FOXP3 (1; 0.33%), RAB27A (1; 0.33%), LRBA (1; 0.33%) |
| Congenital defects of phagocyte number or function | CYBB (7; 2.33%), CYBA (3; 1.0%), FERMT3 (3; 1.0%), HAX1 (1; 0.33%), ELANE (6; 2.0%), SBDS (4; 1.66%), IL-12R (4; 1.66%), ITGβ2 (1; 0.33%), RAC2 (1; 0.33%), GATA2 (2; 0.66%), IRF8 (1; 0.33%) |
| Defects in intrinsic and innate immunity | STAT1 (4; 1.66%), SMARCAL1 (1; 0.33%), CTSC (3; 1.0%) |
| Autoinflammatory disorders | NOD2 (5; 1.66%), MVK (2; 0.66%), ADA2 (2; 0.66%), NLRP3 (5; 1.0%), MEVF (5; 1.66%), NLRP12 (3; 1.0%), NFAT5 (1; 0.33%), TNFRSF1A (1; 0.33%) |
| Complement deficiencies | CD59 (1; 0.33%) |
| Bone marrow failure | TINF2 (3; 1.0%), TCN2 (1; 0.33%), FANCC (1; 0.33%), RTEL1 (1; 0.33%), TERT (1; 0.33%) |

The J Project has spread and achieved a significant success not only in the number of diagnosed patients, but also in arranging their treatment. In 2011, the National Cooperation in the field of PID was established with colleagues from Poland, Hungary, Belarus, and Iran [9, 10].

The J Project has also gradually transformed from an educational campaign for physicians to a collaborative research program aimed at identifying the mutational spectrum of genes associated with PID and analyzing unique genotype-phenotypic relationships in Eastern and Central Europe. Thus, in 2011, two groups of researchers from different countries (one group included L. Chernyshova, A. Bondarenko, and V. Chernyshov from Ukraine) described a new variant of chronic mucocutaneous candidiasis (CMCC) caused by gain-of-function mutations in the NLRP12 gene [11-14].

As of today, within the framework of the Cooperation Agreement, a scientific project is jointly being implemented with the Republican Centre of Pediatric Oncology, Hematology and Immunology of Belarus – “The genetic landscape of SCID in Eastern Europe” – according to the grant of the scientific program CHILDREN (Jeffrey Modell Foundation, JMF) [15, 16].

The support in genetic diagnosis enabled us to diagnose several PIDs and study the clinical features and prevalence of immunodeficiencies in the Ukraine. The results of these scientific studies were summarized in research theses and articles, presented at conferences [17-21]. Given that PIDs are rare diseases, we can make reasonable conclusions only based on collecting, summarizing and analyzing data from different countries. The results of multicenter studies of patients with various PIDs are important for the development of novel methods of treatment. Such results are presented in publications of scientific teams combining efforts of scientists from different countries [22-26].

### Progress with treatment of primary immunodeficiency disease

The J Project has spread and achieved a significant success not only in the number of diagnosed patients, but also in arranging their treatment. In 2011, the National
Program of Replacement Therapy with Intravenous Immunoglobulin for Children with Predominant Antibody Deficiencies was approved. In 2019, a similar program was approved for adult patients. To date, all 194 patients with primary immunodeficiencies requiring replacement therapy with immunoglobulins are provided with medications. Most patients receive intravenous immunoglobulin, but in 2019, 16.1% of children and 26.2% of adults switched to subcutaneous immunoglobulin.

Hematopoietic stem cell transplantation (HSCT) was performed in 40 PID patients out of 156 children potentially needing this treatment. It was successful for 30 children. In the National Clinic OCHMATDYT, HSCT was performed successfully from family donors to six children with PIDs [WAS – 3, CGD – 1, hyper-IgE syndrome (mutation of DOCK8) – 1, and CMCC (STAT1 GOF mutation) – 1]. Most patients with PID were transplanted in clinics of other countries [27]. Among other treatments for patients with PID are sirolimus for children with autoimmune lymphoproliferative syndrome (ALPS) and activated PI3K delta syndrome (APDS), colony-stimulating factor for patients with neutropenia, abatacept for patients with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) haplo-insufficiency, and some children with PID receive antibacterial and antifungal prophylaxis. Children with autoinflammatory disorders are treated with interleukin 1 (IL-1) antagonists, colchicine and monoclonal antibodies against tumor-necrosis factor. The therapy with C1-inhibitor for patients with hereditary angioedema will start soon.

Significant support and success in achieving the J Project core goals have been reached through the activity of the non-governmental organization Rare Immune Diseases, which was founded in 2014 and represents the interests of the patient community. Progress in the J Project contributed to an increase in the number of identified patients and their integration, and introduction of other countries’ experience in patient communities. In our country, the patient and professional communities are in close friendships, helping and supporting each other in achieving common goals.

Development of regional immunological centers (Lviv, Ternopil)

The Western Ukrainian Center for Pediatric Immunology in Lviv led by Professor L. Kostyuchenko, has been working hosted by the multidisciplinary children hospital Western Ukrainian Specialized Pediatric Medical Centre since 2001. In 2019, the center joined the Pediatric Rheumatology Service and was renamed as the Western Ukrainian Clinic of Pediatric Immunology and Rheumatology, which has opened new opportunities for successful detection and treatment of immunodeficiencies of the group of autoinflammatory syndromes.

The database of patients with PIDs numbers over 300 patients and is one of the largest in Ukraine. In cooperation with the Institute of Hereditary Pathology of the National Academy of Medical Sciences of Ukraine, genetic diagnosis of Nijmegen syndrome was established and a database of patients and their families was created. Prenatal diagnosis was carried out in high-risk families with Nijmegen syndrome. The Western Ukrainian Clinic of Pediatric Immunology and Rheumatology actively cooperates with European centers which solve similar problems, including issues of genetic diagnostics of immunodeficiencies and their treatment.

With successful operation of the J Project in Ukraine, one more new center has been established recently. To improve PID detection in the Ternopil region, the enthusiastic group lead by Prof. O. Boyarchuk launched the project entitled “Implementation of the model of combined physician education and public awareness of the infrastructure to diagnose primary immunodeficiency diseases in children” in 2016. The project received support from the Jeffrey Modell Foundation. The major aim of this project was to improve PID detection in children at early stages through implementation of the methodology combining education of the physicians, increased public awareness, immunological testing, and effective medical support at various stages of PIDs. Education of primary care physicians and other specialists on early PID detection in every district of the Ternopil region raised the awareness of PIDs and improved early diagnosis. Within the first 2 years of the program the number of detected PIDs increased almost threefold, and in comparison to the two-year period before the initiation of the awareness campaign (2015-2016), it was almost fivefold higher (2 cases/year before vs. 9 cases/year during the awareness campaign) [28].

Collaboration with other Ukrainian pediatric immunology centers and colleagues from Poland, the USA (Yale University Pediatric Genomics Discovery Program, Dr. Carrie Lucas), Belarus, and Greece was very fruitful [29-35]. The center continues the implementation of the J Project principles in the regional centers and conducts targeted screening of children at risk of PID. The group is enthusiastic to start a pilot study in Ukraine on the neonatal screening of PIDs through quantifying T-cell receptor excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs) to identify T- and B-cell lymphopenia.

Central European Journal of Immunology 2021; 46(2): 255
Collaboration between the countries involved in the J Project and other countries in the field of molecular diagnosis of PID is vital. On the other hand, we should develop on-site molecular genetic laboratories and update the existing laboratories in Ukraine.

In conclusion, the future perspectives of the J Project in Ukraine include the development of professional multidisciplinary cooperation in management of patients with PIDs, change of formats of measures on raising the awareness of PIDs among the medical fraternity (consulting help to doctors in regions for active identification of patients with PIDs, expanding the audience of health workers, the dissemination of information on PIDs among the population), and conducting educational activities among nurses. It is critically important to improve PID diagnoses, including genetic diagnosis, and ensure access to all necessary treatment for PID patients. We should direct all our efforts towards the development of a bone marrow donor registry and HSCT in Ukraine.

Acknowledgements

We thank Professor Laszlo Marodi, Malgorzata Pac, Ewa Bernatovska, Biopharma, Octapharma, the Jeffrey Modell Foundation, the Kyiv Children’s Immunological Centre, doctors, patients, and parents for their generous support and active participation in running the J Project in Ukraine.

The authors declare no conflict of interest.

References

1. Marodi L, Abolhassani H, Aghamohamaddi A (2019): Fifteen years of the J Project. J Clin Immunol 39: 363-369.
2. Chernysheva L, Bondarenko A, Kostyuchenko L, et al. (2015): Epidemiology of primary immunodeficiency in Ukraine according to the register of patients. Childs Health 7: 16-23.
3. Tangye SG, Al-Herz W, Bousfiha A, et al. (2019): Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 40: 24-64.
4. ESID Registry – Working Definitions for Clinical Diagnosis of PID. ESID Clin Crit_oimrn_orpha_hpo_11_2019fin
5. Grimbacher B, ESID Registry Working Party (2014): The European Society for Immunodeficiencies (ESID) registry 2014. Clin Exp Immunol 178: 18-20.
6. Knerr V, Gathmann B, Anne-Marie Eades-Perner AM, et al. (2008): Die ESID-Online-Datenbank für primäre Immunodefekte Erste Analysen mit Blick auf Deutschland und Europa. Med Klin 103: 620-627.
7. Toth B, Volokha A, Mihai A, et al. (2009): Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study. Mol Immunol 46: 2140-2146.
8. Tadej A, Bataneant M, Belevtsev M, et al. (2011): The creation and progress of the J Project in Eastern and Central Europe. Ann NY Acad Sci 1238: 65-73.
9. Sharapova SO, Guryanova IE, Pashchenko OE (2016): Molecular characteristics, clinical and immunologic manifestations of 11 children with Omenn syndrome in Eastern Europe. J Clin Immunol 36: 46-55.
10. Pediatric immunology. A case-based collection with MCQs. Vol. 2. Rezaei N (Ed.). Springer, Cham 2019.
11. Liu L, Okada S, Kong XF, et al. (2011): Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208: 1635-1648.
12. Soltész B, Tóth B, Shabashova N, et al. (2013): New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet 50: 567-578.
13. Toubiana J, Satoshi Okada, Hiller J, Oleastro M, et al. (2017): Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127: 3154-3164.
14. Volokha A, Chernyshova L, Bondarenko A, Marodi L (2014): Different severity of phenotypes in patients with GOF STAT1 mutation. J Clin Immunol 34: 703-704.
15. Sharapova S, Skomska-Pawliszak M, Rodina Y, et al. (2019): The clinical and genetic spectrum of RAG deficiency including a c. 256_257delAA founder variant in Slavic countries. J Clin Immunol 39: S131-S132.
16. Sharapova S, Haapaniemki E, Sakovich I, et al. (2019): Heterozygous activating mutation in RAC2 causes infantile-onset combined immunodeficiency with susceptibility to viral infections. Clin Immunol 205: 1-5.
17. Bondarenko A, Chernyshova L, Volokha A, et al. (2016): Molecular genetic characteristics of primary immunodeficiency in Ukraine. Hematology. Transfusiology. Eastern Europe 2: 13-23.
18. Bondarenko A, Chernyshova L, Sychova I (2014): Lung and brain aspergillosis in patient with autosomal recessive chronic granulomatous disease. J Clin Immunol 34: 705.
19. Gulácsy V, Freiberger T, Shcherbina A, et al. (2011): J Project Study Group: Genetic characteristics of eighty-seven patients with the Wiskott-Aldrich syndrome. Mol Immunol 48: 788-792.
20. Krivan G, Chernyshova L, Kostyuchenko L, et al. (2017): A multicentre study on the efficacy, safety and pharmacokinetics of IqYmune®, a highly purified 10% liquid intravenous immunoglobulin, in patients with primary immune deficiency. J Clin Immunol 37: 539-547.
21. Marodi L, Cypowyj S, Tóth B, Chernyshova L (2012): Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol 130: 1019-1027.
22. Bozutk K, Germeshausen M, Avedillo Diez I, et al. (2008): Multiple independent second-site mutations in two siblings with somatic mosaicism for Wiskott-Aldrich syndrome. Clin Genet 74: 68-74.
23. Conti F, Lugo-Reyes SO, Blancas Galicia L, et al. (2016): Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases J Allergy Clin Immunol 138: 241-248.
24. Glasmacher J, Tanja C Bittner et al. (2016): Wiskott-Aldrich syndrome: a retrospective study on 575 patients analyzing the impact of splenectomy, stem cell transplantation, or no defin-
itive treatment on frequency of disease-related complications and physician-perceived quality of life. Blood 128: 366.
25. Rosain J, Oleaga-Quintas C, Deswarte C, et al. (2018): A variety of Alu-mediated copy number variations can underlie IL-12Rβ1 deficiency. J Clin Immunol 38: 617-627.
26. El-Sayed ZA, Abramova I, Aldave JC, et al. (2019): X-linked agammaglobulinemia (XLA): Phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J 12: 100018.
27. Barzaghi F, Minniti F, Mauro M, et al. (2019): ALPS-like phenotype caused by ADA2 deficiency rescued by allogeneic hematopoietic stem cell transplantation. Front Immunol 9: 2767.
28. Boyarchuk O, Volokha A, Hariyan T, et al. (2019): The impact of combining educational program with the improving of infrastructure to diagnose on early detection of primary immunodeficiencies in children. Immunol Res 67: 390-397.
29. Boyarchuk O, Volyanska L, Dmytrash L (2017): Clinical variability of chromosome 22q11.2 deletion syndrome. Cent Eur J Immunol 42: 412-417.
30. Boyarchuk O, Lewandowicz-Uszyńska A, Kinash M, et al. (2018): Physicians’ awareness concerning primary immunodeficiencies in the Ternopil Region of Ukraine. Pediatra Polska 93: 221-228.
31. Boyarchuk O, Volyanska L, Kosovska T, et al. (2018): Awareness about primary immunodeficiency diseases among medical students. Georgian Med News 12: 124-130.
32. Boyarchuk O (2018): Allergic manifestations of primary immunodeficiency diseases and its treatment approaches. Asian J Pharma Clin Res 11: 83-90.
33. Boyarchuk O, Kinash M, Hariyan T, Bakalyuk T (2019): Evaluation of knowledge about primary immunodeficiencies among postgraduate medical students. Arch Balk Med Union 54: 11-19.
34. Boyarchuk O, Dmytrash L (2019): Clinical manifestations in the patients with primary immunodeficiencies: data from one regional center. Turk J Immunol 7: 113-119.
35. Boyarchuk O, Balatska N, Chornomydyz I (2019): Evaluation of warning signs of primary immunodeficiencies. Pediatra Polska 94: 337-341.